Equal-WT
WhaleScore 2.0
?
DEEP TRACK CAPITAL, LP
GREENWICH CT
Investment Advisor
Hedge Fund
Deep Track Capital is based out of Greenwich. Deep Track Capital is a hedge fund with 3 clients and discretionary assets under management (AUM) of $5,194,322,737 (Form ADV from 2025-03-31). Their last reported 13F filing for Q1 2025 included $3,088,173,822 in managed 13F securities
and a top 10 holdings concentration of 53.08%. Deep Track Capital's largest holding is Intra-Cellular Therapies Inc with shares held of 2,000,000. Whalewisdom has at least 15 13F filings, 3 13D filings, and 242 13G filings
Investment Strategy
Deep Track seeks to generate superior risk-adjusted returns by investing in the life sciences industry. They primarily utilize fundamentally driven due diligence strategies aimed at capitalizing on the dispersion in outcomes amongst biotechnology development companies. Deep Track believes this dispersion is driven by high rates of scientific complexity, binary outcomes in clinical trials and regulatory decisions, as well as inefficiencies in capital allocation and varying degrees of quality in governance and management.
The Funds also employ long/short investment strategies, which depend on Deep Track's ability to identify and purchase undervalued securities and sell short overvalued securities. There may be rare circumstances where Deep Track believes a portfolio company is undervalued and would benefit from an activist investment strategy. Deep Track will invest principally in publicly traded, and, to a lesser extent, in privately held, biotechnology, specialty pharmaceuticals, medical device, diagnostics and life sciences tools and.
Other Contact Information
(Subscription Required)
2025-03-31
Top Buys (13F)
| Name | % Change |
|---|---|
| PTGX Protagonist Therapeu | 3.26% |
| AKRO Akero Therapeutics I | 2.66% |
| TARS Tarsus Pharmaceutica | 2.47% |
| BBIO BridgeBio Pharma Inc | 2.3% |
| IONS Ionis Pharmaceutical | 1.94% |
2025-03-31
Top Sells (13F)
| Name | % Change |
|---|---|
| SWTX SpringWorks Therapeu | 4.66% |
| PLRX Pliant Therapeutics, | 2.7% |
| HRMY Harmony Biosciences | 1.86% |
| NMRA Neumora Therapeutics | 1.58% |
| GMAB Genmab A/S | 1.56% |
2025-03-31
13F Holdings Summary
| Name | $ Change |
|---|---|
| ITCI Intra-Cellular Thera | 8.54% |
| GH Guardant Health Inc | 7.51% |
| DVAX Dynavax Technologies | 7.47% |
| IMVT Immunovant Inc | 5.26% |
| PTGX Protagonist Therapeu | 4.7% |
2025-03-31
13F Activity
| Market Value | $3.09b, Prior: $2.68b |
| Inflows (Outflows) as % of Total MV | +21.8878% |
| New Purchases | 16 stocks |
| Added To | 25 stocks |
| Sold out of | 10 stocks |
| Reduced holdings in | 8 stocks |
| Top 10 Holdings % | 53.08% |
| Turnover %[1] | 32.91% |
| Turnover Alt %[2] | 12.7% |
| Time Held Top 20 | 2.2 quarters |
| Time Held Top 10 | 1.8 quarters |
| Time Held All | 3.87 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2025-03-31
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2025-03-31
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2025-03-31